ArticleOncology letters2019
Tanshinone IIA induces apoptosis of ovarian cancer cells
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 34 citations in OpenAlex.
- Tanshinone IIA inhibits epithelial-mesenchymal transition in ovarian cancer by promoting NR3C2 transcriptional activation of ING1.iScience · 2026Article
- Recent Update Targeting Autophagy-Apoptosis Crosstalk Using Bioactive Natural Products for Ovarian Cancer Treatment.Biomedicines · 2026Review
- Natural Metabolites as Modulators of Sensing and Signaling Mechanisms: Unlocking Anti-Ovarian Cancer Potential.Biomedicines · 2025Review
- Signaling pathways behind the biological effects of tanshinone IIA for the prevention of cancer and cardiovascular diseases.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Importance of Advanced Detection Methodologies from Plant Cells to Human Microsystems Targeting Anticancer Applications.International journal of molecular sciences · 2025Review
- Tanshinone II A Facilitates Chemosensitivity of Osteosarcoma Cells to Cisplatin via Activation of p38 MAPK Pathway.Chinese journal of integrative medicine · 2025Article
- An Update on Physiopathological Roles of Akt in the ReprodAKTive Mammalian Ovary.Life (Basel, Switzerland) · 2024Review
- Silver nitroprusside as an efficient chemodynamic therapeutic agent and a peroxynitrite nanogenerator for targeted cancer therapies.Journal of advanced research · 2024Article
- IGF1R inhibition and PD-1 blockade improve anti-tumor immune response in epithelial ovarian cancer.Frontiers in oncology · 2024Article
- Tanshinone IIA targeting cell signaling pathways: a plausible paradigm for cancer therapy.Pharmacological reports : PR · 2023Review
- The mechanisms of tanshinone in the treatment of tumors.Frontiers in pharmacology · 2023Review
- Efficacy and Mechanism of Quercetin in the Treatment of Experimental Colitis Using Network Pharmacology Analysis.Molecules (Basel, Switzerland) · 2022Article
- Exploring the Antiovarian Cancer Mechanisms of Salvia Miltiorrhiza Bunge by Network Pharmacological Analysis and Molecular Docking.Computational and mathematical methods in medicine · 2022Article
- Activation of CNR1/PI3K/AKT Pathway by Tanshinone IIA Protects Hippocampal Neurons and Ameliorates Sleep Deprivation-Induced Cognitive Dysfunction in Rats.Frontiers in pharmacology · 2022Article
- Review
- Applications for natural deep eutectic solvents in Chinese herbal medicines.Frontiers in pharmacology · 2022Review
- PSMC2/CCND1 axis promotes development of ovarian cancer through regulating cell growth, apoptosis and migration.Cell death & disease · 2021Article
- Novel Single Inhibitor of HDAC6/8 and Dual Inhibitor of PI3K/HDAC6 as Potential Alternative Treatments for Prostate Cancer.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Recent Research Progress (2015-2021) and Perspectives on the Pharmacological Effects and Mechanisms of Tanshinone IIA.Frontiers in pharmacology · 2021Review
- Anticancer Effect of Tanshinones on Female Breast Cancer and Gynecological Cancer.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is one of the most common gynecological tumors and is the second most common cause of gynecological cancer-associated mortality worldwide. Tanshinone IIA (Tan-IIA) possesses anticancer activities through inducing the apoptosis of tumor cells. The purpose of the present study was to analyze the ability of Tan-IIA to induce apoptosis of human ovarian cancer cells
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.